Theunis Theodorus Cloete

Theunis Theodorus Cloete

Auto-generated profile, based on publicly available information

Theunis Theodorus Cloete

Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2023 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Open access
AHAnja Haasbroek-Pheiffer
Anja Haasbroek-Pheiffer
SNSuzanne Elaine van Niekerk
Suzanne Elaine van Niekerk
FKFrank van der Kooy
Frank van der Kooy
TCTheunis Cloete
Theunis Cloete
JSJan Steenekamp
Jan Steenekamp
Josias HammanJosias Hamman
Josias Hamman
The intranasal route of administration provides a noninvasive method to deliver drugs into the systemic circulation and/or directly into the brain. Direct nose‐to‐brain drug delivery offers the possibility to treat central nervous system diseases more effectively, as it can evade the blood–brain barrier. In vitro and ex vivo intranasal models provide a means to investigate physiological and pharmaceutical factors that could play a role in drug delivery across the nasal epithelium as well as to determine the mechanisms involved in drug absorption from the nose. The development and implementation of cost‐effective pharmacokinetic models for intranasal drug delivery with good in vitro‐in vivo correlation can accelerate pharmaceutical drug product development and improve economic and ecological aspects by reducing the time and costs spent on animal studies. Special considerations should be made with regard to the purpose of the in vitro/ex vivo study, namely, whether it is intended to predict systemic or brain delivery, source and site of tissue or cell sampling, viability window of selected model, and the experimental setup of diffusion chambers. The type of model implemented should suit the relevant needs and requirements of the project, researcher, and interlaboratory. This review aims to provide an overview of in vitro and ex vivo models that have been developed to study intranasal and direct nose‐to‐brain drug delivery.

1 February 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
LTLouis Thesnaar
Louis Thesnaar
JBJaco J. Bezuidenhout
Jaco J. Bezuidenhout
APAnél Petzer
Anél Petzer
JPJacobus Petrus Petzer
Jacobus Petrus Petzer
TCTheunis T. Cloete
Theunis T. Cloete

8 December 2020 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Janke KleynhansJanke Kleynhans
Janke Kleynhans
Gerhardus - Gert Hendrik KrugerGerhardus - Gert Hendrik Kruger
Gerhardus - Gert Hendrik Kruger
TCTheunis Cloete
Theunis Cloete
JZJan Rijn Zeevaart
Jan Rijn Zeevaart
TEThomas Ebenhan
Thomas Ebenhan
This review describes the usefulness of in silico design approaches in the design of new radiopharmaceuticals, especially peptide-based radiotracers (including peptidomimetics). Although not part of the standard arsenal utilized during radiopharmaceutical design, the use of in silico strategies is steadily increasing in the field of radiochemistry as it contributes to a more rational and scientific approach. The development of new peptide-based radiopharmaceuticals as well as a short introduction to suitable computational approaches are provided in this review. The first section comprises a concise overview of the three most useful computeraided drug design strategies used, namely i) a Ligand-based Approach (LBDD) using pharmacophore modelling, ii) a Structure-based Design Approach (SBDD) using molecular docking strategies and iii) Absorption-Distribution-Metabolism-Excretion-Toxicity (ADMET) predictions. The second section summarizes the challenges connected to these computer-aided techniques and discusses successful applications of in silico radiopharmaceutical design in peptide-based radiopharmaceutical development, thereby improving the clinical procedure in Nuclear Medicine. Finally, the advances and future potential of in silico modelling as a design strategy is highlighted.

7 November 2023 in Results in Chemistry
Verified
Journal Article
Open access
AHAlize Hoepfner
Alize Hoepfner
APAnél Petzer
Anél Petzer
JPJacobus P. Petzer
Jacobus P. Petzer
JPJudey Pretorius
Judey Pretorius
TCTheunis T. Cloete
Theunis T. Cloete

26 February 2023 in Results in Chemistry
Verified
Journal Article
Open access
MSMaryké Shaw
Maryké Shaw
APAnél Petzer
Anél Petzer
JPJacobus P. Petzer
Jacobus P. Petzer
TCTheunis T. Cloete
Theunis T. Cloete

31 January 2026 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Open access
PDF file
MSMaryké Shaw
Maryké Shaw
APAnél Petzer
Anél Petzer
CCChantalle Crous
Chantalle Crous
TCTheunis T. Cloete
Theunis T. Cloete
JPJacobus Petrus Petzer
Jacobus Petrus Petzer
The monoamine oxidase (MAO) enzymes are mitochondrial flavoenzymes that catalyse the oxidative deamination of neurotransmitter amines such as serotonin, norepinephrine and dopamine. Inhibitors of the MAOs are well-known antidepressant and antiparkinsonian agents, and act by reducing MAO-mediated metabolism of neurotransmitters in the brain. The present study attempted to identify compounds that inhibit the MAOs by virtual screening of existing drugs listed in the DrugBank using the Discovery Studio life science software. To identify the combinations of docking and scoring functions that most accurately identify known MAO inhibitors, the enrichment factor (EF 10% ) and area under the receiver operating characteristic curve (ROC-AUC) were evaluated. As a third validation metric, ligands that have been complexed with the MAOs were redocked and the root mean square deviation (RMSD) from the co-crystallized orientation was measured. The LibDock/LigScore 2 combination yielded the best results for both MAO-A (EF 10% : 5.20, ROC-AUC: 0.82) and MAO-B (EF 10% : 7.47, ROC-AUC: 0.89). Among the top 100 hits, ten compounds were selected and evaluated as in vitro inhibitors of human MAO. Guanabenz (IC 50 = 3.46 µM) and proflavine (IC 50 = 0.223 µM) were found to be the most potent MAO-A inhibitors. These compounds also inhibited MAO-B with IC 50 values of 8.49 and 34.3 µM, respectively. Kinetic analysis showed a competitive mode of MAO-A inhibition for guanabenz (K i = 0.16 µM) and proflavine (K i = 0.066 µM). These results show that the validated virtual screening protocol is a useful tool to aid in the discovery of MAO inhibitors. Graphical abstract